BRUSSELS : The European Union drugs regulator is set to authorise the use of two monoclonal antibodies to treat COVID-19 patients in coming days, two EU sources told Reuters, in its first approvals of such therapies.
The authorisations would come as the bloc faces a new surge in infections and hospitalisations despite high vaccination levels in many countries.
The European Medicines Agency (EMA) will this week give the green light to the treatment developed by U.S. biotech firm Regeneron and Swiss giant Roche, one source said.
The cocktail of antibodies is known as REGEN-COV in the United States, and is sold elsewhere under the brand name Ronapreve.